These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1557 related items for PubMed ID: 24687000

  • 21. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
    McAlister FA, Renin Angiotension System Modulator Meta-Analysis Investigators.
    Eur Heart J; 2012 Feb; 33(4):505-14. PubMed ID: 22041554
    [Abstract] [Full Text] [Related]

  • 22. Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis.
    Shen JI, Saxena AB, Montez-Rath ME, Leng L, Chang TI, Winkelmayer WC.
    J Nephrol; 2017 Apr; 30(2):281-288. PubMed ID: 27485007
    [Abstract] [Full Text] [Related]

  • 23. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T, Mancia G, Volpe M.
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [Abstract] [Full Text] [Related]

  • 24. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
    Mayyas F, Bataineh W, Jarab A.
    Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
    [Abstract] [Full Text] [Related]

  • 25. ACEIs for cardiovascular risk reduction--have we taken our eye off the ball?
    Sindone A, Erlich J, Perkovic V, Suranyi M, Newman H, Lee C, Barin E, Roger SD.
    Aust Fam Physician; 2013 Sep; 42(9):634-8. PubMed ID: 24024224
    [Abstract] [Full Text] [Related]

  • 26. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction.
    Driscoll A, Currey J, Tonkin A, Krum H.
    Cochrane Database Syst Rev; 2015 Dec 21; 2015(12):CD009889. PubMed ID: 26689943
    [Abstract] [Full Text] [Related]

  • 27. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC, Huang KW, Yen DJ, Hu CJ, Lin CL, Kao CH.
    Int J Cardiol; 2016 Oct 01; 220():462-6. PubMed ID: 27390970
    [Abstract] [Full Text] [Related]

  • 28. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ, Chu H, Ou SM, Chen YT.
    Int J Cardiol; 2015 Nov 15; 199():283-9. PubMed ID: 26218587
    [Abstract] [Full Text] [Related]

  • 29. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials.
    Akbari A, Knoll G, Ferguson D, McCormick B, Davis A, Biyani M.
    Perit Dial Int; 2009 Nov 15; 29(5):554-61. PubMed ID: 19776050
    [Abstract] [Full Text] [Related]

  • 30. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS.
    JAMA; 2003 May 21; 289(19):2534-44. PubMed ID: 12759325
    [Abstract] [Full Text] [Related]

  • 31. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.
    Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG, REACH Registry Investigators*.
    Heart; 2017 Sep 21; 103(17):1339-1346. PubMed ID: 28285267
    [Abstract] [Full Text] [Related]

  • 32. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC, Heran BS, Wright JM.
    Cochrane Database Syst Rev; 2014 Aug 22; 2014(8):CD009096. PubMed ID: 25148386
    [Abstract] [Full Text] [Related]

  • 33. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD, Kolber MR, Loewen P, Ellis U, McCormack JP.
    PLoS One; 2019 Aug 22; 14(2):e0212907. PubMed ID: 30817783
    [Abstract] [Full Text] [Related]

  • 34. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
    Al Khalaf MM, Thalib L, Doi SA.
    Am J Cardiovasc Drugs; 2009 Aug 22; 9(1):29-43. PubMed ID: 19178130
    [Abstract] [Full Text] [Related]

  • 35. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials.
    Song HF, Wang S, Li HW.
    Chin Med J (Engl); 2012 May 22; 125(10):1804-10. PubMed ID: 22800904
    [Abstract] [Full Text] [Related]

  • 36. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
    Batty JA, Tang M, Hall M, Ferrari R, Strauss MH, Hall AS.
    Syst Rev; 2018 Aug 25; 7(1):131. PubMed ID: 30144828
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B.
    PLoS Med; 2016 Mar 25; 13(3):e1001971. PubMed ID: 26954482
    [Abstract] [Full Text] [Related]

  • 38. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
    Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR.
    Vasc Med; 2015 Jun 25; 20(3):237-44. PubMed ID: 25835349
    [Abstract] [Full Text] [Related]

  • 39. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.
    Madrid AH, Peng J, Zamora J, Marín I, Bernal E, Escobar C, Muños-Tinoco C, Rebollo JM, Moro C.
    Pacing Clin Electrophysiol; 2004 Oct 25; 27(10):1405-10. PubMed ID: 15511250
    [Abstract] [Full Text] [Related]

  • 40. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
    Ohtsubo T, Shibata R, Kai H, Okamoto R, Kumagai E, Kawano H, Fujiwara A, Kitazono T, Murohara T, Arima H.
    Hypertens Res; 2019 May 25; 42(5):641-649. PubMed ID: 30948834
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 78.